Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
14. Januar 2025 07:00 ET
|
Instil Bio
ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China ...
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
13. November 2024 07:00 ET
|
Instil Bio
Licensed SYN-2510, a potential best-in-class PD-L1xVEGF bispecific antibody, for global ex-China development and commercialization Clinical data update for SYN-2510/IMM2510 in China from ImmuneOnco...
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
16. September 2024 06:00 ET
|
Instil Bio
Global registrational strategy in first-line non-squamous and squamous non-small cell lung cancer (NSCLC)Global registrational strategy in first-line triple-negative breast cancer (TNBC)Initiation of...
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
13. August 2024 17:00 ET
|
Instil Bio
In-licensed SYN-2510/IMM2510, a potentially best-in-class PD-L1xVEGF bispecific antibody, and SYN-27M/IMM27M, a next-generation ADCC-enhanced anti-CTLA-4 antibodyEntered into a 15-year lease for our...
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
01. August 2024 06:00 ET
|
Instil Bio
DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced...
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
10. Mai 2024 07:00 ET
|
Instil Bio
DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its...
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
21. März 2024 17:00 ET
|
Instil Bio
DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported...
Instil Bio Announces Strategic Update
16. Januar 2024 08:00 ET
|
Instil Bio
DALLAS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte,...
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
05. Dezember 2023 17:00 ET
|
Instil Bio
DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte,...
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
13. November 2023 17:00 ET
|
Instil Bio
DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies...